Is MAINZ BIOMED N.V. (MYNZ) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 31.5% / 30% | 60.0% / 30% | 2.1% / 30% | 241.3% / 5% | ✗ NOT HALAL |
| DJIM | 31.5% / 33% | 60.0% / 33% | 2.1% / 33% | 241.3% / 5% | ✗ NOT HALAL |
| MSCI | 24.7% / 33% | 47.1% / 33% | 1.6% / 33% | 241.3% / 5% | ✗ NOT HALAL |
| S&P | 31.5% / 33% | 60.0% / 33% | 2.1% / 33% | 241.3% / 5% | ✗ NOT HALAL |
| FTSE | 24.7% / 33% | 47.1% / 33% | 1.6% / 50% | 241.3% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 67.5% | |
| Operating Margin | -2822.1% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -114.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$17M |
| Free Cash Flow | -$17M |
| Total Debt | $3M |
| Debt-to-Equity | 122.6 |
| Current Ratio | 0.5 |
| Total Assets | $13M |
Price & Trading
| Last Close | $0.82 |
| 50-Day MA | $0.92 |
| 200-Day MA | $1.35 |
| Avg Volume | 625K |
| Beta | 0.3 |
|
52-Week Range
$0.55
| |
About MAINZ BIOMED N.V. (MYNZ)
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is MAINZ BIOMED N.V. (MYNZ) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), MAINZ BIOMED N.V. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is MAINZ BIOMED N.V.'s debt ratio?
MAINZ BIOMED N.V.'s debt ratio is 31.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 24.7%.
What are MAINZ BIOMED N.V.'s key financial metrics?
MAINZ BIOMED N.V. has a market capitalization of $11M, and revenue of $893,991.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.